سعر مايزنت 0.25مجم 120 قرص 2025

Siponimod 0.25 mg film-coated tablets, pack of 120, Novartis (Egypt scientific office); sphingosine 1-phosphate receptor modulator for multiple sclerosis.

• Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (incidence 10% or more): headache, hypertension and transaminase increases.International label, same product · DailyMed (U.S. National Library of Medicine)

• CYP2C9*3/*3 genotype; in the last 6 months myocardial infarction, unstable angina, stroke, TIA, or decompensated heart failure requiring hospitalization or NYHA class III/IV heart failure; Mobitz type II second-degree, third-degree AV block or sick sinus syndrome unless a functioning pacemaker is present; hypersensitivity to siponimod or excipients.International label, same product · DailyMed (U.S. National Library of Medicine)

• Increased risk of infections, including serious and opportunistic infections such as progressive multifocal leukoencephalopathy (PML); check a recent CBC before starting; avoid live vaccines during and for 4 weeks after treatment.International label, same product · DailyMed (U.S. National Library of Medicine)
• Macular edema (especially with diabetes or uveitis history): ophthalmic evaluation before starting and when visual changes occur.International label, same product · DailyMed (U.S. National Library of Medicine)
• Transient decrease in heart rate and AV conduction delays at treatment initiation; obtain an ECG before starting; first-dose 6-hour monitoring for patients with sinus bradycardia, first- or second-degree (Mobitz I) AV block, or history of MI or heart failure.International label, same product · DailyMed (U.S. National Library of Medicine)

• Antiarrhythmic drugs, QT-prolonging drugs and drugs that decrease heart rateNot studied with class Ia or III antiarrhythmics; additive effects on heart rate; seek cardiology advice.DailyMed (U.S. National Library of Medicine)
• Beta-blockersAdditive heart-rate lowering at initiation; start only if resting heart rate is above 50 bpm on stable beta-blocker therapy.DailyMed (U.S. National Library of Medicine)
• Live attenuated vaccinesAvoid during treatment and for 4 weeks after; stop siponimod 1 week before and 4 weeks after a planned live vaccine.DailyMed (U.S. National Library of Medicine)

• No adequate human data; based on animal data and mechanism of action, siponimod can cause fetal harm (embryotoxicity, fetotoxicity, teratogenicity in animals).International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; siponimod is excreted in rat milk; consider benefits of breastfeeding and the mother's clinical need.International label, same product · DailyMed (U.S. National Library of Medicine)

English text not available for this section.